BCRX vs PBH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BCRX · BioCryst Pharmaceuticals$7.22 ▼ 1.37%
PBH · Prestige Consumer Healthcare$49.63 ▲ 0.06%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BCRX +5.7%
- PBH -13.6%
Head to head
| Metric | BCRX | PBH |
|---|---|---|
| Price | $7.22 | $49.63 |
| Change today | ▼ 1.37% | ▲ 0.06% |
| Market cap | $1.86B | $2.35B |
| Return, 3 months | -25.4% | -4.6% |
| Return, year to date | -7.4% | -19.5% |
| Return, 1 year | +3.6% | -16.5% |
| P/E (TTM) | – | 15.3 |
| P/B | -4.7 | 1.2 |
| P/E percentile vs own 5y | 70th | 39th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +13.1% | +22.7% |
| Net profit growth (YoY) | +193.9% | -40.1% |
| Gross margin | 97.9% | 52.5% |
| Operating margin | 42.5% | 25.0% |
| Net margin | -37.4% | 13.3% |
| Return on equity | – | 8.2% |
| Analyst target vs. price | +135.5% | +41.0% |
| Analyst buy share | 67% | 100% |
| RSI (14) | 35 | 56 |
| 30-day volatility | 40.4% | 67.1% |
| Max drawdown, 1 year | -35.0% | -38.8% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PBH is the largest of the group by market value.
- BCRX has returned the most over the past year.
- PBH is growing revenue fastest.
- PBH keeps the most profit per dollar of sales.
- BCRX has been the calmest stock over the last 30 days.